The following are excerpts from the recent report by the Office of the Inspector General, U.S. Department of Justice on the Drug Enforcement Administration’s (DEA) regulatory and enforcement efforts to control the diversion of opioids.
In response to the release of the U.S. Department of Justice Office of the Inspector General's Review of the Drug Enforcement Administration’s (DEA) Regulatory and Enforcement Efforts to Control the Diversion of Opioids, John Parker, Senior Vice President of Communications with the Healthcare Distribution Alliance (HDA) released the following statement.
The Healthcare Distribution Alliance (HDA) released the following statement regarding media reporting on the Ensuring Patient Access and Effective Drug Enforcement Act of 2016.
The fundamental premise of recent media coverage — that the passage of the Ensuring Patient Access and Effective Drug Enforcement Act of 2016 (EPAEDEA) weakened the Drug Enforcement Administration’s (DEA) enforcement authority during the opioid crisis — is factually incorrect.
The Healthcare Distribution Alliance (HDA) released the following statement on the release of the “Safe Importation Action Plan” by the Department of Health and Human Services (HHS) and U.S. Food and Drug Administration (FDA).
John Parker
(703) 885-0216
Farah Simonett
(703) 885-0269
